Glucagon/GLP-1 dual agonism adds glucagon-receptor activation to the GLP-1 backbone, recruiting hepatic energy expenditure and lipid mobilization on top of GLP-1's appetite suppression. The structural feature is what differentiates the next-generation incretin candidates from semaglutide and tirzepatide.
Lead programs covered on this site: Boehringer Ingelheim and Zealand Pharma's survodutide (BI 456906) — Phase 3 SYNCHRONIZE-1 reported 16.6% mean weight loss at 76 weeks (April 28, 2026), predominantly fat-mass loss with lean-mass preservation, and Phase 3 LIVERAGE / LIVERAGE-Cirrhosis trials are underway in MASH following 83% Phase 2 histological improvement. AstraZeneca's AZD9550 is the GLP-1/glucagon dual leg of the ASCEND triple-mechanism program with selective amylin AZD6234. Retatrutide adds GIP on top of GLP-1 + glucagon for triple agonism — a related but distinct architecture.
The dual-agonist class is being measured against tirzepatide's GLP-1/GIP combination on weight loss, against semaglutide on cardiovascular outcomes, and against retatrutide on the upper bound of efficacy. Stories here cover the SYNCHRONIZE and ASCEND readouts, partnership economics, and the broader incretin landscape. See #survodutide, #azd9550, and #triple-agonist.
AstraZeneca's ASCEND program is active in Phase 2b, combining AZD9550 (GLP-1 + glucagon dual agonist) with AZD6234 (selective amylin analog) in a two-molecule triple-mechanism strategy aimed at fat-selective weight loss and organ protection. Individual assets are also in Phase 2. The combination reflects the February 2026 $1.2 billion CSPC Pharmaceuticals collaboration that brought both molecules into AstraZeneca's portfolio, alongside elecoglipron (AZD5004 / ECC5004), the small-molecule oral GLP-1 that posted 5.8% weight loss over four weeks in Phase 1b in China. AstraZeneca enters the next-gen obesity race later than Lilly, Novo, Roche, and Boehringer, but the triple-mechanism positioning targets the safety + organ-protection lane that competitors leave open.
Boehringer Ingelheim and Zealand Pharma announced positive topline results from the Phase 3 SYNCHRONIZE-1 trial of survodutide (BI 456906), a glucagon/GLP-1 dual agonist, in adults with obesity or overweight without type 2 diabetes. Adults treated with survodutide achieved 16.6% mean weight loss at 76 weeks (efficacy estimand) versus 3.2% placebo (p<0.0001), with up to 85.1% of treated adults achieving ≥5% weight reduction. Up to 39.2 lb (17.8 kg) average weight loss; initial analysis indicates predominantly fat-tissue loss with lean mass contributing only a small proportion. Full data will be presented at ADA 2026 in June.
Boehringer Ingelheim confirmed completion of the 76-week primary endpoint visit for the last participant in Phase 3 SYNCHRONIZE-1. Topline data expected H1 2026 — making it one of the year's most anticipated obesity readouts. Survodutide is a glucagon/GLP-1 dual agonist co-developed with Zealand Pharma. The comprehensive SYNCHRONIZE program also includes SYNCHRONIZE-CVOT (cardiovascular outcomes, fully enrolled). All key trials are scheduled to read out at scientific meetings throughout 2026, potentially paving the way for regulatory submission as the third major obesity GLP-1-class drug after semaglutide and tirzepatide.